Table 6 Uni- and multivariate association of CDR1-AS, hsa-miR-7 and other clinical variables with PFS in the predictive cohort.

Parameters base model	univariate model				multivariate model
Parameters base model	n	HR	(95% CI)	P	HR	(95% CI)	P
	188
Age at start 1 ^st -line tamoxifen
≤55 years	75	1			1
56–70 years	67	0.76	(0.54–1.07)	0.11	0.78	(0.54–1.13)	0.19
>70 years	46	0.57	(0.38–0.84)	*0.005*	0.65	(0.43–0.98)	*0.039*
Disease-free interval
≤1 year	76	1			1
1–3 years	48	0.79	(0.54–1.14)	0.21	0.83	(0.56–1.22)	0.34
>3 years	64	0.68	(0.48–0.97)	*0.032*	0.74	(0.51–1.05)	0.09
Dominant site of relapse
Local regional	21	1			1
Bone	101	1.60	(0.96–2.65)	0.071	1.99	(1.16–3.43)	*0.013*
Other distant metastasis	66	1.34	(0.78–2.27)	0.28	2.00	(1.10–3.63)	*0.023*
Hormone/growth factor receptors*
ER (log continuous ESR1)	188	0.77	(0.67–0.89)	<*0.001*	0.82	(0.69–0.96)	*0.016*
PR (log continuous PGR)	188	0.89	(0.83–0.96)	*0.002*	0.92	(0.84–0.96)	*0.038*
HER2 (ERBB2) status
Not amplified	165	1			1
Amplified	23	1.86	(1.19–2.90)	*0.007*	1.49	(0.89–2.50)	0.13
					*hsa-miR-7* separately added to the base model
*CDR1-AS* (log continuous)	188	0.97	(0.86–1.10)	0.62
*hsa-miR-7* (log continuous)	188	1.18	(1.04–1.33)	*0.008*	1.22	(1.08–1.38)	*0.002*
≤median	94	1			1
>median	94	1.54	(1.14–2.09)	*0.005*	1.63	(1.18–2.25)	*0.003*

This table shows the associations of PFS with the cohort characteristics and CDR1-AS and hsa-miR-7 expression. The different metrics were examined with an univariate analysis on the left side of the table, while they were analysed with a multivariate model on the right side. n = number of patients, HR = hazard ratio, CI = confidence interval, and P = p-value. Significant p-values are printed in bold. The hormone/growth factor receptor expression values used in this table were determined by qPCR. *Cut-offs for positive and negative hormone/growth factor status were established as previously described^56,57.

Search